Should incidental findings discovered with whole-genome sequencing or testing be sought and
reported to ordering clinicians and to patients (or their surrogates)?—Yes.
The use of genomic sequencing in medicine is increasing substantially as this technology becomes
less expensive and of demonstrated diagnostic utility.1,2 Potentially clinically relevant incidental findings from clinical
exome or genome sequencing (hereafter referred to as genomic sequencing) will arise whenever an
individual undergoes genomic sequencing. There is a great deal of controversy regarding how such
findings should be addressed by clinical sequencing laboratories because many possible findings are
of medical interest and processes for genomic testing and interpretation are not yet standardized.
To date, the traditions of genetic testing and reporting have exceptionalized all genetic risk
information as potentially dangerous to the well-being of patients. This tradition, in the era of
genome sequencing, must be reconsidered.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 17
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.